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Abstract: Botulinum toxin A is increasingly used in the treatment of idiopathic and symptomatic 
headache disorders. However, only few controlled trials are available and many trials can hardly 
be compared to each other because of different endpoints and different trial designs. In particular 
chronic daily headache, which is deﬁ  ned as an idiopathic headache occurring on more than 15 days 
per month for at least 3 months and a daily duration of at least 4 hours, is considered as a headache 
disorder with possible efﬁ  cacy of botulinum toxin A. For the prophylactic treatment of chronic 
tension-type headache and chronic migraine, no sufﬁ  cient positive evidence for a successful treat-
ment can be obtained from randomized, double-blind, and placebo-controlled trials to date. For 
the treatment of chronic daily headache including medication overuse headache, there is some 
positive evidence for efﬁ  cacy in a subgroup of patients. To date, the majority of double-blind and 
placebo-controlled studies do not suggest that botulinum toxin A is efﬁ  cacious in the treatment 
of chronic idiopathic headache disorders. However, it is possible that some subgroups of patients 
with chronic daily headache will beneﬁ  t from a long-term treatment with botulinum toxin A.
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Introduction
After the ﬁ  rst case reports, open studies, and preliminary reviews on the efﬁ  cacy of 
botulinum toxin in pain therapy, the use of this substance for the treatment of headache 
disorders has been discussed widely (Mathew and Kaup 2002; Argoff 2003; Dodick 
2003; Evers 2004; Blumenfeld et al 2004). However, the interpretations of the ﬁ  ndings 
in trials and case series are conﬂ  icting and inconsistent. In this paper, the published 
evidence based on the placebo-controlled, double-blind trials for the prophylaxis of 
chronic daily headache with botulinum toxin A will be analysed. This analysis is based 
on literature research in medical databases (Medline, Embase, Current Contents, Science 
Citation Index) from 1995 to 2007 and on published congress reports of the relevant 
headache and pain congresses. Key words were botulinum and chronic headache.
Chronic daily headache is deﬁ  ned as headache occurring on at least 15 days per 
month for at least three months and with a daily duration of at least four hours a day 
(Silberstein and Lipton 2000). Per deﬁ  nition and per classiﬁ  cation of the IHS, the fol-
lowing four entities are differentiated: chronic migraine, chronic tension-type headache, 
hemicrania continua and new onset daily persistent headache. These types can occur 
with and without medication overuse. This means that medication overuse headache 
is not separately considered in the classiﬁ  cation system of chronic daily headache.
Only studies on the prophylactic treatment of headache were considered. As recom-
mended by the International Headache Society (IHS), headache frequency was regarded 
the most important primary endpoint (Schoenen 1995; Tfelt-Hansen et al 2000). The 
diagnosis of cervicogenic headache and studies on patients with different coexisting or 
with other headache diagnoses were not considered.Neuropsychiatric Disease and Treatment 2007:3(6) 762
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Trials on headache treatment
In Table 1, the studies on botulinum toxin in the prophy-
lactic treatment of chronic tension-type headache (one trial 
also with episodic tension-type headache) according to the 
IHS criteria are listed. Ten randomized, double-blind, and 
placebo-controlled studies on patients suffering from tension-
type headache were included (Göbel et al 1999; Smuts et al 
1999; Rollnik et al 2000; Burch et al 2001; Schmitt et al 
2001; Schulte-Mattler and Krack 2004; Kokoska et al 2004; 
Padberg et al 2004; Empl et al 2005; Silberstein et al 2006). 
Apart from one, all these studies were negative for the pri-
mary endpoint and did not show any efﬁ  cacy of botulinum 
toxin in reduction of headache frequency or intensity. The 
only study with a signiﬁ  cant reduction of headache days in 
the treatment group but not in the placebo group, however, 
did not perform a formal statistical comparison between the 
two groups (Smuts et al 1999). In one long-term blinded and 
placebo-controlled study, the efﬁ  cacy of botulinum toxin 
was maintained over a year in some patients (Relja and 
Klepac 2001). In some secondary endpoints such as headache 
intensity or headache duration, a positive trend or signiﬁ  cant 
subgroup analysis could be observed. In particular, patients 
with mixed headache and migrainous headache showed 
beneﬁ  t. The studies used different doses (25 to over 100 IU
Botox® and up to 240 IU Dysport®) and injection sites mak-
ing a direct comparison difﬁ  cult. The design of these stud-
ies mainly followed the guidelines of the IHS for studies 
on tension-type headache (Schoenen 1995) including the 
diagnosis according to the ﬁ  rst (Headache Classiﬁ  cation 
Committee 1988) and the second (Headache Classiﬁ  cation 
Committee 2004) version of the IHS criteria for chronic 
tension-type headache (dull, bilateral, moderate headache 
on more than 15 days per month).
In summary, all but one randomized, double-blind, and 
placebo-controlled studies on botulinum toxin in the prophy-
lactic treatment of chronic tension-type headache showed 
negative results for the primary endpoint.
In unspeciﬁ  c chronic daily headache, very recently larger 
studies have been performed since it has been suggested from 
observational studies that these patients might show the most 
beneﬁ  t from botulinum toxin. The randomized, double-blind, 
and placebo-controlled studies on this headache type are 
listed in Table 2. Three different studies (Ondo et al 2004; 
Silberstein et al 2005; Mathew et al 2005; Freitag et al 2006) 
Table 1 Randomized, double-blind, placebo-controlled studies on botulinum toxin in the prophylactic treatment 
of tension-type headache
Reference  Indication to treatment  Number  Results compared with placebo
   of  patients
Göbel et al 1999  chronic tension-type headache  10  No signiﬁ  cant reduction of pain intensity, head-
      ache hours, or use of analgesics
Smuts et al 1999  chronic tension-type headache  41  Signiﬁ  cant reduction of headache intensity
      and pain-free days in month 3 compared with
      baseline data in group with botulinum
      toxin but not in placebo group
Rollnik et al 2000  chronic tension-type headache  21  No signiﬁ  cant differences between botulinum
       toxin and placebo in all headache parameters
Burch et al 2001  episodic and chronic tension-  41  No signiﬁ  cant difference in headache frequency
 type  headache     
Schmitt et al 2001   chronic tension-type headache  59  No signiﬁ  cant differences between botulinum 
      toxin and placebo in all headache parameters
Schulte-Mattler  chronic tension-type headache  113  No signiﬁ  cant reduction in all efﬁ  cacy endpoints
and Krack 2004     
Ka et al 2004  chronic tension-type headache  40  No signiﬁ  cant reduction of headache frequency; 
     signiﬁ  cant reduction of pain intensity
Padberg et al 2004  chronic tension-type headache  40  No signiﬁ  cant results
  
Empl et al 2005  chronic tension-type headache  125  No signiﬁ  cant results
 
Silberstein et al 2006  chronic tension-type headache  300  No signiﬁ  cant difference in headache frequency 
      (primary endpoint) for all treatment groups
      (treatment with 150 U was signiﬁ  cantly inferior
       to placebo); signiﬁ  cant increase in percentage of 
      responders for three treatment groupsNeuropsychiatric Disease and Treatment 2007:3(6) 763
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showed a negative result for the primary endpoint. However, 
preplanned subgroup analyses of one study (Mathew et al 
2005) showed signiﬁ  cant improvements for patients with no 
other prophylactic treatment and for patients with chronic 
migraine with or without medication overuse (Dodick et al 
2005; Elkind et al 2005).
There are no published controlled trials on the use of 
botulinum toxin A in the treatment of hemicrania continua 
and of new onset daily persistent headache.
Conclusion
In this review, the current published data on botulinum toxin in 
the treatment of chronic daily headache was analysed regarding 
all published double-blind and placebo-controlled trials. This 
analysis showed that a general efﬁ  cacy of this therapy cannot be 
postulated to date. After a period of very optimistic case series 
and open studies, we are now able to analyse placebo-controlled 
and double-blind studies. This evidence-based approach gives 
us a more pessimistic picture showing no consistent efﬁ  cacy of 
botulinum toxin in idiopathic headache disorders. For chronic 
tension-type headache, nearly all randomized, double-blind, 
placebo-controlled trials showed negative results. In summary, 
pure idiopathic headache disorders cannot be regarded as an 
indication for botulinum toxin to date.
For chronic daily headache, no consistent results can 
be obtained from randomized, double-blind, and placebo-
controlled trials. However, analysing subgroups of these stud-
ies enables the identiﬁ  cation of patients who might beneﬁ  t from 
botulinum toxin. It is likely that those patients with chronic 
daily headache (with or without medication oversue) who are 
severely impaired (ie, highest loss of productivity) and who 
are not receiving any other prophylactic treatment are the 
appropriate group of patients with a beneﬁ  t from botulinum 
toxin. Since this total patient group shows a prevalence of up to 
4% in population based epidemiological studies (Stovner et al 
2006), it is warranted to further elucidate the clinical efﬁ  cacy 
of botulinum toxin in this subgroup. In this context it should 
be noted that a subgroup of patients with exploding headache 
quality (in contrast to imploding or ocular headache quality) 
showed a good response to botulinum toxin suggesting that 
allodynia is an important predictor for the probability that 
botulinum toxin is efﬁ  cacious (Jakubowski et al 2006).
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